

Matthias W Beckmann

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6435033/publications.pdf>

Version: 2024-02-01

154
papers

8,153
citations

94433

37
h-index

53230

85
g-index

166
all docs

166
docs citations

166
times ranked

12216
citing authors

#	ARTICLE	IF	CITATIONS
1	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. <i>Nature Genetics</i> , 2013, 45, 353-361.	21.4	960
2	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 371-384.	21.4	493
3	Circulating Tumor Cells Predict Survival in Early Average-to-High Risk Breast Cancer Patients. <i>Journal of the National Cancer Institute</i> , 2014, 106, .	6.3	493
4	Genome-wide association studies identify four ER negative-specific breast cancer risk loci. <i>Nature Genetics</i> , 2013, 45, 392-398.	21.4	374
5	CWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. <i>Nature Genetics</i> , 2013, 45, 362-370.	21.4	326
6	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. <i>Nature Genetics</i> , 2010, 42, 874-879.	21.4	321
7	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. <i>Nature Genetics</i> , 2010, 42, 885-892.	21.4	309
8	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. <i>Nature Genetics</i> , 2009, 41, 996-1000.	21.4	276
9	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. <i>Nature Genetics</i> , 2020, 52, 572-581.	21.4	265
10	Dose-Response Association of CD8 ⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. <i>JAMA Oncology</i> , 2017, 3, e173290.	7.1	260
11	Genome-wide association analysis identifies three new breast cancer susceptibility loci. <i>Nature Genetics</i> , 2012, 44, 312-318.	21.4	256
12	Common variants at 19p13 are associated with susceptibility to ovarian cancer. <i>Nature Genetics</i> , 2010, 42, 880-884.	21.4	235
13	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. <i>Nature Genetics</i> , 2015, 47, 164-171.	21.4	221
14	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. <i>Nature Communications</i> , 2013, 4, 1628.	12.8	144
15	Genome-wide association study identifies a common variant associated with risk of endometrial cancer. <i>Nature Genetics</i> , 2011, 43, 451-454.	21.4	141
16	Pregnancies and live births after 20 transplantations of cryopreserved ovarian tissue in a single center. <i>Fertility and Sterility</i> , 2015, 103, 462-468.	1.0	130
17	Prenatal Correction of X-Linked Hypohidrotic Ectodermal Dysplasia. <i>New England Journal of Medicine</i> , 2018, 378, 1604-1610.	27.0	113
18	Pattern of SMARCB1 (INI1) and SMARCA4 (BRG1) in poorly differentiated endometrioid adenocarcinoma of the uterus: analysis of a series with emphasis on a novel SMARCA4-deficient dedifferentiated rhabdoid variant. <i>Annals of Diagnostic Pathology</i> , 2015, 19, 198-202.	1.3	102

#	ARTICLE	IF	CITATIONS
19	Gene panel sequencing in familial breast/ovarian cancer patients identifies multiple novel mutations also in genes others than BRCA1/2. <i>International Journal of Cancer</i> , 2017, 140, 95-102.	5.1	99
20	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. <i>Nature Communications</i> , 2013, 4, 1627.	12.8	98
21	The influence of obesity on survival in early, high-risk breast cancer: results from the randomized SUCCESS A trial. <i>Breast Cancer Research</i> , 2015, 17, 129.	5.0	93
22	Single nucleotide polymorphisms of the aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2008, 112, 89-98.	2.5	77
23	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. <i>American Journal of Human Genetics</i> , 2015, 96, 5-20.	6.2	76
24	Shifting cancer care towards Multidisciplinarity: the cancer center certification program of the German cancer society. <i>BMC Cancer</i> , 2017, 17, 850.	2.6	68
25	Ovarian Tissue Transplantation: Experience From Germany and Worldwide Efficacy. <i>Clinical Medicine Insights Reproductive Health</i> , 2019, 13, 117955811986735.	3.9	62
26	Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer. <i>BMC Cancer</i> , 2018, 18, 1051.	2.6	59
27	BRCA mutations and their influence on pathological complete response and prognosis in a clinical cohort of neoadjuvantly treated breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2018, 171, 85-94.	2.5	56
28	Impact of disease progression on health-related quality of life in patients with metastatic breast cancer in the PRAEGNANT breast cancer registry. <i>Breast</i> , 2018, 37, 154-160.	2.2	56
29	ABCB1 (MDR1) polymorphisms and ovarian cancer progression and survival: A comprehensive analysis from the Ovarian Cancer Association Consortium and The Cancer Genome Atlas. <i>Gynecologic Oncology</i> , 2013, 131, 8-14.	1.4	55
30	Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors – Data from the German PRAEGNANT breast cancer registry. <i>Breast</i> , 2018, 37, 42-51.	2.2	54
31	Effects of whole-body electromyostimulation combined with individualized nutritional support on body composition in patients with advanced cancer: a controlled pilot trial. <i>BMC Cancer</i> , 2018, 18, 886.	2.6	48
32	Electrospun patterned porous scaffolds for the support of ovarian follicles growth: a feasibility study. <i>Scientific Reports</i> , 2019, 9, 1150.	3.3	48
33	Fertility protection: complications of surgery and results of removal and transplantation of ovarian tissue. <i>Reproductive BioMedicine Online</i> , 2018, 36, 188-196.	2.4	47
34	Pooled analysis of the prognostic relevance of progesterone receptor status in five German cohort studies. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 143-151.	2.5	45
35	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. <i>PLoS ONE</i> , 2015, 10, e0128106.	2.5	44
36	Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry. <i>Cancers</i> , 2019, 11, 10.	3.7	43

#	ARTICLE	IF	CITATIONS
37	Fumarate hydratase (FH) deficiency in uterine leiomyomas: recognition by histological features versus blind immunoscreening. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2018, 472, 789-796.	2.8	42
38	Efficacy of neoadjuvant pertuzumab in addition to chemotherapy and trastuzumab in routine clinical treatment of patients with primary breast cancer: a multicentric analysis. <i>Breast Cancer Research and Treatment</i> , 2019, 173, 319-328.	2.5	40
39	Genetic Predisposition to In Situ and Invasive Lobular Carcinoma of the Breast. <i>PLoS Genetics</i> , 2014, 10, e1004285.	3.5	39
40	Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. <i>European Journal of Cancer</i> , 2021, 155, 1-12.	2.8	39
41	Expression of Neuroendocrine Markers in Different Molecular Subtypes of Breast Carcinoma. <i>BioMed Research International</i> , 2014, 2014, 1-9.	1.9	38
42	Long-Term Endurance Exercise in Humans Stimulates Cell Fusion of Myoblasts along with Fusogenic Endogenous Retroviral Genes In Vivo. <i>PLoS ONE</i> , 2015, 10, e0132099.	2.5	37
43	Xenotransplantation of cryopreserved human ovarian tissue—a systematic review of MII oocyte maturation and discussion of it as a realistic option for restoring fertility after cancer treatment. <i>Fertility and Sterility</i> , 2015, 103, 1557-1565.	1.0	35
44	Prognostic effect of Ki-67 in common clinical subgroups of patients with HER2-negative, hormone receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 175, 617-625.	2.5	35
45	Collective forces of tumor spheroids in three-dimensional biopolymer networks. <i>ELife</i> , 2020, 9, .	6.0	35
46	Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer – Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany. <i>Breast</i> , 2020, 54, 88-95.	2.2	34
47	Review. Fertility preservation for young female cancer patients. <i>In Vivo</i> , 2009, 23, 123-30.	1.3	34
48	Genome-Wide Association Study Identifies a Possible Susceptibility Locus for Endometrial Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2012, 21, 980-987.	2.5	32
49	Genetic variants in VEGF pathway genes in neoadjuvant breast cancer patients receiving bevacizumab: Results from the randomized phase III GeparQ into study. <i>International Journal of Cancer</i> , 2015, 137, 2981-2988.	5.1	31
50	Filtration based assessment of CTCs and CellSearch® based assessment are both powerful predictors of prognosis for metastatic breast cancer patients. <i>BMC Cancer</i> , 2018, 18, 204.	2.6	30
51	Hormone replacement therapy and prognosis in ovarian cancer patients. <i>European Journal of Cancer Prevention</i> , 2013, 22, 52-58.	1.3	28
52	Predicting attention deficit hyperactivity disorder using pregnancy and birth characteristics. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 889-895.	1.7	28
53	Meconium Indicators of Maternal Alcohol Abuse during Pregnancy and Association with Patient Characteristics. <i>BioMed Research International</i> , 2014, 2014, 1-11.	1.9	27
54	Computerized patient identification for the EMBRACA clinical trial using real-time data from the PRAEGNANT network for metastatic breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2016, 158, 59-65.	2.5	27

#	ARTICLE	IF	CITATIONS
55	Endometriosis as a risk factor for ovarian or endometrial cancer – results of a hospital-based case-control study. <i>BMC Cancer</i> , 2015, 15, 751.	2.6	25
56	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). <i>Journal of Genetics and Genome Research</i> , 2015, 2, .	0.3	25
57	Genetic risk factors for ovarian cancer and their role for endometriosis risk. <i>Gynecologic Oncology</i> , 2017, 145, 142-147.	1.4	24
58	Gynecologic oncologists' attitudes and practices relating to integrative medicine: results of a nationwide AGO survey. <i>Archives of Gynecology and Obstetrics</i> , 2017, 296, 295-301.	1.7	24
59	Implementation and Feasibility of Electronic Patient-Reported Outcome (ePRO) Data Entry in the PRAEGNANT Real-Time Advanced and Metastatic Breast Cancer Registry. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 870-878.	1.8	24
60	Update Breast Cancer 2018 (Part 2) – Advanced Breast Cancer, Quality of Life and Prevention. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 246-259.	1.8	23
61	Polymorphisms in Inflammation Pathway Genes and Endometrial Cancer Risk. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 216-223.	2.5	22
62	Epithelial-Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. <i>Genetic Epidemiology</i> , 2015, 39, 689-697.	1.3	22
63	Outcome and prognosis in uterine sarcoma and malignant mixed Mullerian tumor. <i>Archives of Gynecology and Obstetrics</i> , 2016, 294, 343-351.	1.7	21
64	Ovarian tissue cryopreservation and retransplantation – what do patients think about it?. <i>Reproductive BioMedicine Online</i> , 2016, 32, 394-400.	2.4	21
65	Predicting Triple-Negative Breast Cancer Subtype Using Multiple Single Nucleotide Polymorphisms for Breast Cancer Risk and Several Variable Selection Methods. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 667-678.	1.8	21
66	Prognostic Impact of Weight Change During Adjuvant Chemotherapy in Patients With High-Risk Early Breast Cancer: Results From the ADEBAR Study. <i>Clinical Breast Cancer</i> , 2018, 18, 175-183.	2.4	21
67	Pathway-Based Analysis of Genome-Wide Association Data Identified SNPs in HMMR as Biomarker for Chemotherapy- Induced Neutropenia in Breast Cancer Patients. <i>Frontiers in Pharmacology</i> , 2018, 9, 158.	3.5	21
68	Update Breast Cancer 2018 (Part 1) – Primary Breast Cancer and Biomarkers. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 237-245.	1.8	20
69	Knowledge and attitudes regarding medical research studies among patients with breast cancer and gynecological diseases. <i>BMC Cancer</i> , 2015, 15, 587.	2.6	19
70	Mammographic density is the main correlate of tumors detected on ultrasound but not on mammography. <i>International Journal of Cancer</i> , 2016, 139, 1967-1974.	5.1	19
71	Major and minor complications after anterior rectal resection for deeply infiltrating endometriosis. <i>Archives of Gynecology and Obstetrics</i> , 2017, 295, 1277-1285.	1.7	19
72	Update Breast Cancer 2017 – Implementation of Novel Therapies. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 1281-1290.	1.8	19

#	ARTICLE	IF	CITATIONS
73	Heart Rate Measurement Accuracy of Fitbit Charge 4 and Samsung Galaxy Watch Active2: Device Evaluation Study. <i>JMIR Formative Research</i> , 2022, 6, e33635.	1.4	19
74	Digit ratio (2D:4D) and behavioral symptoms in primary-school aged boys. <i>Early Human Development</i> , 2018, 119, 1-7.	1.8	18
75	Characterization of Molecular Subtypes of Paget Disease of the Breast Using Immunohistochemistry and In Situ Hybridization. <i>Archives of Pathology and Laboratory Medicine</i> , 2019, 143, 206-211.	2.5	18
76	Addition of triple negativity of breast cancer as an indicator for germline mutations in predisposing genes increases sensitivity of clinical selection criteria. <i>BMC Cancer</i> , 2018, 18, 926.	2.6	16
77	The safety and satisfaction of ovarian tissue cryopreservation in prepubertal and adolescent girls. <i>Reproductive BioMedicine Online</i> , 2020, 40, 547-554.	2.4	16
78	Endogenous Retroviral K Envelope Is a Novel Tumor Antigen and Prognostic Indicator of Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2021, 11, 657187.	2.8	16
79	Association between breast cancer risk factors and molecular type in postmenopausal patients with hormone receptor-positive early breast cancer. <i>Breast Cancer Research and Treatment</i> , 2019, 174, 453-461.	2.5	15
80	HLA-G and HLA-F protein isoform expression in breast cancer patients receiving neoadjuvant treatment. <i>Scientific Reports</i> , 2020, 10, 15750.	3.3	15
81	Gemcitabine as adjuvant chemotherapy in patients with high-risk early breast cancer—results from the randomized phase III SUCCESS-A trial. <i>Breast Cancer Research</i> , 2020, 22, 111.	5.0	15
82	Preliminary observations on whole-ovary xenotransplantation as an experimental model for fertility preservation. <i>Reproductive BioMedicine Online</i> , 2014, 29, 621-626.	2.4	14
83	Variation in NF- κ B Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2014, 23, 1421-1427.	2.5	13
84	Does stimulation with human gonadotropins and gonadotropin-releasing hormone agonist enhance and accelerate the developmental capacity of oocytes in human ovarian tissue xenografted into severe combined immunodeficient mice?. <i>Fertility and Sterility</i> , 2014, 101, 1477-1484.e3.	1.0	13
85	Accelerated Partial Breast Irradiation: Macrophage Polarisation Shift Classification Identifies High-Risk Tumours in Early Hormone Receptor-Positive Breast Cancer. <i>Cancers</i> , 2020, 12, 446.	3.7	13
86	Macromastia: an economic burden? A disease cost analysis based on real-world data in Germany. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 521-531.	1.7	13
87	Mammographic density and prognosis in primary breast cancer patients. <i>Breast</i> , 2021, 59, 51-57.	2.2	13
88	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. <i>Oncotarget</i> , 2016, 7, 72381-72394.	1.8	13
89	Semi-automated delineation of breast cancer tumors and subsequent materialization using three-dimensional printing (rapid prototyping). <i>Journal of Surgical Oncology</i> , 2017, 115, 238-242.	1.7	12
90	Tumour-Infiltrating Inflammatory Cells in Early Breast Cancer: An Underrated Prognostic and Predictive Factor?. <i>International Journal of Molecular Sciences</i> , 2020, 21, 8238.	4.1	12

#	ARTICLE	IF	CITATIONS
91	Association of genomic variants at the human leukocyte antigen locus with cervical cancer risk, HPV status and gene expression levels. <i>International Journal of Cancer</i> , 2020, 147, 2458-2468.	5.1	12
92	Adjuvant radiotherapy and local recurrence in vulvar cancer – a subset analysis of the AGO-CaRE-1 study. <i>Gynecologic Oncology</i> , 2022, 164, 68-75.	1.4	12
93	Course of Ovarian Hyperstimulation Syndrome in 19 Intact Twin Pregnancies After Assisted Reproduction Techniques, With a Case Report of Severe Thromboembolism. <i>Twin Research and Human Genetics</i> , 2006, 9, 691-696.	0.6	11
94	Gynecologists' attitudes toward and use of complementary and integrative medicine approaches: results of a national survey in Germany. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 967-980.	1.7	11
95	History of Comorbidities and Survival of Ovarian Cancer Patients, Results from the Ovarian Cancer Association Consortium. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 1470-1473.	2.5	10
96	Initial clinical results with a fusion prototype for mammography and three-dimensional ultrasound with a standard mammography system and a standard ultrasound probe. <i>Acta Radiologica</i> , 2018, 59, 1406-1413.	1.1	10
97	Major and minor complications after resection without bowel resection for deeply infiltrating endometriosis. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 991-999.	1.7	10
98	Genetic predictors of chemotherapy-related amenorrhea in women with breast cancer. <i>Fertility and Sterility</i> , 2019, 112, 731-739.e1.	1.0	10
99	Impact of fibroblast growth factor receptor 1 (FGFR1) amplification on the prognosis of breast cancer patients. <i>Breast Cancer Research and Treatment</i> , 2020, 184, 311-324.	2.5	10
100	The association between prenatal alcohol consumption and preschool child stress system disturbance. <i>Developmental Psychobiology</i> , 2021, 63, 687-697.	1.6	10
101	Self-reported Improvement in Side Effects and Quality of Life With Integrative Medicine in Breast Cancer Patients. <i>Integrative Cancer Therapies</i> , 2018, 17, 941-951.	2.0	9
102	Assessment of the additional clinical potential of X-ray dark-field imaging for breast cancer in a preclinical setup. <i>Therapeutic Advances in Medical Oncology</i> , 2020, 12, 175883592095793.	3.2	9
103	Patterns and Trends of Herbal Medicine Use among Patients with Gynecologic Cancer. <i>Geburtshilfe Und Frauenheilkunde</i> , 2021, 81, 699-707.	1.8	9
104	CA27.29 as a tumour marker for risk evaluation and therapy monitoring in primary breast cancer patients. <i>Tumor Biology</i> , 2016, 37, 13769-13775.	1.8	8
105	Differential prognostic relevance of patho-anatomical factors among different tumor-biological subsets of breast cancer: Results from the adjuvant SUCCESS A study. <i>Breast</i> , 2019, 44, 81-89.	2.2	8
106	Comparison of preoperative and postoperative sexual function in patients with deeply infiltrating endometriosis with and without bowel resection. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2019, 239, 21-29.	1.1	8
107	Breast MRI texture analysis for prediction of BRCA-associated genetic risk. <i>BMC Medical Imaging</i> , 2020, 20, 86.	2.7	8
108	Repetitive Maturation of Oocytes From Non-Stimulated Xenografted Ovarian Tissue From a Prepubertal Patient Indicating the Independence of Human Ovarian Tissue. <i>Geburtshilfe Und Frauenheilkunde</i> , 2017, 77, 1304-1311.	1.8	7

#	ARTICLE	IF	CITATIONS
109	Breast cancer patients'™ satisfaction with individual therapy goals and treatment in a standardized integrative medicine consultancy service. Archives of Gynecology and Obstetrics, 2018, 298, 147-156.	1.7	7
110	Me2SO perfusion time for whole-organ cryopreservation can be shortened: Results of micro-computed tomography monitoring during Me2SO perfusion of rat hearts. PLoS ONE, 2020, 15, e0238519.	2.5	7
111	Introducing multiple-choice questions to promote learning for medical students: effect on exam performance in obstetrics and gynecology. Archives of Gynecology and Obstetrics, 2020, 302, 1401-1406.	1.7	7
112	Prenatal Alcohol Exposure and the Facial Phenotype in Adolescents: A Study Based on Meconium Ethyl Glucuronide. Brain Sciences, 2021, 11, 154.	2.3	7
113	Association of genomic variants at <sc><i>PAX8</i></sc> and <sc><i>PBX2</i></sc> with cervical cancer risk. International Journal of Cancer, 2021, 149, 893-900.	5.1	7
114	Factors Influencing Decision-Making for or against Adjuvant and Neoadjuvant Chemotherapy in Postmenopausal Hormone Receptor-Positive Breast Cancer Patients in the EvAluate-TM Study. Breast Care, 2016, 11, 315-322.	1.4	6
115	Using automated texture features to determine the probability for masking of a tumor on mammography, but not ultrasound. European Journal of Medical Research, 2017, 22, 30.	2.2	6
116	Cost effectiveness of bilateral risk-reducing mastectomy and salpingo-oophorectomy. European Journal of Medical Research, 2019, 24, 32.	2.2	6
117	Progression-Free Survival and Overall Survival in Patients with Advanced HER2-Positive Breast Cancer Treated with Trastuzumab Emtansine (T-DM1) after Previous Treatment with Pertuzumab. Cancers, 2020, 12, 3021.	3.7	6
118	Association of Prenatal Alcohol Exposure and Prenatal Maternal Depression with Offspring Low-Grade Inflammation in Early Adolescence. International Journal of Environmental Research and Public Health, 2021, 18, 7920.	2.6	6
119	Prevalence of SARS-CoV-2 in Pregnant Women Assessed by RT-PCR in Franconia, Germany: First Results of the SCENARIO Study (SARS-CoV-2 prevalence in pregnant women and at birth in Franconia). Geburtshilfe Und Frauenheilkunde, 2022, 82, 226-234.	1.8	6
120	Aspects of molecular diagnostics and therapy in obstetrics and gynecology. Expert Review of Molecular Diagnostics, 2003, 3, 279-287.	3.1	5
121	Diagnostic Accuracy of Breast Medical Tactile Examiners (MTEs): A Prospective Pilot Study. Breast Care, 2019, 14, 41-47.	1.4	5
122	Risk of postmenopausal hormone therapy and patient history factors for the survival rate in women with endometrial carcinoma. Archives of Gynecology and Obstetrics, 2020, 301, 289-294.	1.7	5
123	RANKL and OPG and their influence on breast volume changes during pregnancy in healthy women. Scientific Reports, 2020, 10, 5171.	3.3	5
124	Variable Expression of the Disialoganglioside GD2 in Breast Cancer Molecular Subtypes. Cancers, 2021, 13, 5577.	3.7	5
125	MUC1 (CA27.29) before and after Chemotherapy and Prognosis in High-Risk Early Breast Cancer Patients. Cancers, 2022, 14, 1721.	3.7	5
126	Economic Constraints - the Growing Challenge for Western Breast Cancer Centers. Breast Care, 2013, 8, 41-47.	1.4	4

#	ARTICLE	IF	CITATIONS
127	Treatment Landscape and Prognosis After Treatment with Trastuzumab Emtansine. <i>Geburtshilfe Und Frauenheilkunde</i> , 2020, 80, 1134-1142.	1.8	4
128	Recurrent KAT6B/A::KANSL1 Fusions Characterize a Potentially Aggressive Uterine Sarcoma Morphologically Overlapping With Low-grade Endometrial Stromal Sarcoma. <i>American Journal of Surgical Pathology</i> , 2022, 46, 1298-1308.	3.7	4
129	Dose adjustment of cisplatin, etoposide, and ifosfamide according to kidney function: a retrospective analysis and implications for medication safety. <i>Naunyn-Schmiedeberg's Archives of Pharmacology</i> , 2018, 391, 219-229.	3.0	3
130	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. <i>International Journal of Molecular Sciences</i> , 2018, 19, 2473.	4.1	3
131	Using Probability for Pathological Complete Response (pCR) as a Decision Support Marker for Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer Patients – a Survey Among Physicians. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 707-714.	1.8	3
132	Analysis of Oncological Second Opinions in a Certified University Breast and Gynecological Cancer Center in Relation to Complementary and Alternative Medicine. <i>Complementary Medicine Research</i> , 2020, 27, 431-439.	1.2	3
133	Challenges and Opportunities for Real-World Evidence in Metastatic Luminal Breast Cancer. <i>Breast Care</i> , 2021, 16, 108-114.	1.4	3
134	Complementary and alternative medicine (CAM) in women with endometriosis. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2021, 262, 7-12.	1.1	3
135	Comparison of C-Reactive Protein in Dried Blood Spots and Saliva of Healthy Adolescents. <i>Frontiers in Immunology</i> , 2021, 12, 795580.	4.8	3
136	Identification of Two Genetic Loci Associated with Leukopenia after Chemotherapy in Patients with Breast Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 3342-3355.	7.0	3
137	Comparison of dienogest and progesterone effects on uterine contractility in the extracorporeal perfusion model of swine uteri. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2018, 97, 1293-1299.	2.8	2
138	Analysis of Oncological Second Opinions in a Certified University Breast and Gynecological Cancer Center Regarding Consensus between the First and Second Opinion and Conformity with the Guidelines. <i>Breast Care</i> , 2021, 16, 291-298.	1.4	2
139	Comparison of methods for isolation and quantification of circulating cell-free DNA from patients with endometriosis. <i>Reproductive BioMedicine Online</i> , 2021, 43, 788-798.	2.4	2
140	Comprehensive characterization of endometriosis patients and disease patterns in a large clinical cohort. <i>Archives of Gynecology and Obstetrics</i> , 2021, , 1.	1.7	2
141	Supportive Infusions in Integrative Breast and Gynecological Oncology – Report on Patients' Satisfaction and Self-reported Effects and Side Effects. <i>Geburtshilfe Und Frauenheilkunde</i> , 2018, 78, 1129-1137.	1.8	1
142	Total laparoscopic hysterectomy: how does training for surgeons in a standardized operation affect hospitals and patients?. <i>Archives of Gynecology and Obstetrics</i> , 2018, 298, 763-771.	1.7	1
143	Can a University Reproductive Medicine Centre Be Financed Under the Pre-Existing General Conditions in Germany?. <i>Geburtshilfe Und Frauenheilkunde</i> , 2019, 79, 63-71.	1.8	1
144	Heregulin (HRG) assessment for clinical trial eligibility testing in a molecular registry (PRAEGNANT) in Germany. <i>BMC Cancer</i> , 2020, 20, 1091.	2.6	1

#	ARTICLE	IF	CITATIONS
145	Discordance between Primary Breast Cancer and Ipsilateral Breast Cancer Tumor Recurrence as a Function of Distance. <i>Journal of Clinical Medicine</i> , 2020, 9, 4033.	2.4	1
146	Feasibility of internal inguinoperitoneal drainage after inguinofemoral lymphadenectomy in vulvar cancer. <i>Archives of Gynecology and Obstetrics</i> , 2020, 301, 1513-1519.	1.7	1
147	Genetic variants in the glucocorticoid pathway genes and birth weight. <i>Archives of Gynecology and Obstetrics</i> , 2021, 303, 427-434.	1.7	1
148	Active Participation, Mindâ€“Body Stabilization, and Coping Strategies with Integrative Medicine in Breast Cancer Patients. <i>Integrative Cancer Therapies</i> , 2021, 20, 153473542199010.	2.0	1
149	OUP accepted manuscript. <i>Human Molecular Genetics</i> , 2022, , .	2.9	1
150	Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics â€“ A retrospective analysis of a real world registry. <i>European Journal of Cancer</i> , 2022, 172, 13-21.	2.8	1
151	Influence of Family History of Breast or Ovarian Cancer on Pathological Complete Response and Long-Term Prognosis in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. <i>Breast Care</i> , 2021, 16, 254-262.	1.4	0
152	Is Reduction Mammoplasty Cost-Effective? A Cost-Utility Analysis of Surgical Treatment for Macromastia in Germany. <i>Breast Care</i> , 2021, 16, 1-9.	1.4	0
153	The G20210A Prothrombin Gene Mutation and the Plasminogen Activator Inhibitor (PAI) 844GG Genotype Increase the Risk of Premature Onset of Severe Preeclampsia.. <i>Blood</i> , 2004, 104, 1050-1050.	1.4	0
154	A phase II single-arm, multicenter, open-label neoadjuvant study of pembrolizumab in combination with nab-paclitaxel followed by pembrolizumab in combination with epirubicin and cyclophosphamide in patients with triple-negative breast cancer: Neoimmunoboost.. <i>Journal of Clinical Oncology</i> , 2020, 38, e12647-e12647.	1.6	0